Clinical observation of priming regimen with pegylated recombinant human granulocyte colony-stimulating factor for treatment of initial treatment elderly patients with acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2019.12.009
- VernacularTitle: 含聚乙二醇化重组人粒细胞集落刺激因子预激方案治疗老年人初治急性髓系白血病的临床观察
- Author:
Mo ZHOU
1
;
Yu SHAO
;
Xueyun SHAN
;
Chunbin WANG
;
Pin WANG
;
Naitong SUN
Author Information
1. Department of Hematology, Yancheng Third People's Hospital of Jiangsu Province, Yancheng 224000, China
- Publication Type:Journal Article
- Keywords:
Leukemia, myeloid, acute;
Polyethylene glycols;
Granulocyte colony-stimulating factor;
Priming regimen
- From:
Journal of Leukemia & Lymphoma
2019;28(12):739-742
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and side effects of priming regimen with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the treatment of initial treatment elderly patients with acute myeloid leukemia (AML).
Methods:Thirty-five elderly patients with early-stage AML (non-M3) who received pre-excitation chemotherapy in Yancheng Third People's Hospital from February 2015 to January 2019 were retrospectively analyzed. According to the different granulocyte colony-stimulating factor (G-CSF) in the chemotherapy regimen, 15 cases were in PEG-rhG-CSF group, 6 mg PEG-rhG-CSF was used alone on day 0 by subcutaneous injection; 20 cases were in recombinant human granulocyte colony-stimulating factor (rhG-CSF) group, 200 μg/m2 rhG-CSF was used per day from day 0 to day 13 by subcutaneous injection, rhG-CSF was suspended or continued according to the number of white blood cells. In addition, both groups were given priming regimen with cytarabine and arubicin, or cytarabine and harringtonine. The efficacy and adverse reactions of the two groups were compared.
Results:In the PEG-rhG-CSF group, there were 5 cases of complete remission, 6 cases of partial remission, 4 cases of non-remission, and 11 cases were effective. In the rhG-CSF group, there were 8 cases of complete remission, 7 cases of partial remission, 5 cases of non-remission, and 15 cases were effective. There was no significant difference in the efficacy between the two groups (χ 2= 0.012, P= 0.911). In terms of adverse reactions, the incidence of infectious fever, bone pain, duration of neutropenia, and duration of thrombocytopenia were not statistically significant (all P > 0.05).
Conclusions:In the pre-excitation chemotherapy for AML, the clinical efficacy and adverse effects of PEG-rhG-CSF are similar to rhG-CSF. However, the use of PEG-rhG-CSF can simplify the operation and reduce the pain and risk of local infection during chemotherapy.
